Literature DB >> 24422551

Diagnostic accuracy of non-invasive fetal RhD genotyping using cell-free fetal DNA: a meta analysis.

Yu-juan Zhu1, Ying-ru Zheng, Li Li, Hao Zhou, Xi Liao, Jian-xin Guo, Ping Yi.   

Abstract

OBJECTIVE: To determine the diagnostic accuracy, validity, current limitations of, and possible solutions to, fetal RhD genotyping from maternal blood based on existing studies written in English.
METHODS: A literature search was conducted that described fetal RhD determination from maternal blood. The number of samples tested, fetal RhD genotype, the source of cell-free fetal DNA, gestational age and fetal Rh type were examined in each study to calculate the accuracy, sensitivity and specificity of fetal RhD genotyping.
RESULTS: Forty-one publications, which included 11,129 samples with non-invasive Rh genotyping of cell-free fetal DNA from maternal blood, were selected. After the exclusion of 352 inconclusive samples, the overall diagnostic accuracy was 98.5% (10,611/10,777), and sensitivity and specificity were 99% and 98%, respectively. First trimester diagnosis showed an accuracy of 99%, higher than second and third trimester diagnosis. Thirty studies reported a 100% diagnostic accuracy of fetal RhD genotyping.
CONCLUSION: Non-invasive fetal RhD genotyping from maternal blood has high accuracy, sensitivity and specificity. METHODS reducing false results have been explored and applied in research. These achievements indicate that this technique will be widely used in routine clinical care.

Entities:  

Keywords:  Fetal RhD; maternal blood; prenatal diagnosis

Mesh:

Substances:

Year:  2014        PMID: 24422551     DOI: 10.3109/14767058.2014.882306

Source DB:  PubMed          Journal:  J Matern Fetal Neonatal Med        ISSN: 1476-4954


  7 in total

Review 1.  Noninvasive Fetal RhD Blood Group Genotyping: A Health Technology Assessment.

Authors: 
Journal:  Ont Health Technol Assess Ser       Date:  2020-11-02

Review 2.  Laboratory Monitoring of Mother, Fetus, and Newborn in Hemolytic Disease of Fetus and Newborn.

Authors:  Morten Hanefeld Dziegiel; Grethe Risum Krog; Anne Todsen Hansen; Marianne Olsen; Birgitte Lausen; Lone Nikoline Nørgaard; Thomas Bergholt; Klaus Rieneck; Frederik Banch Clausen
Journal:  Transfus Med Hemother       Date:  2021-09-08       Impact factor: 3.747

3.  Fetal Rhesus D Genotyping and Sex Determination from Maternal Plasma of Rhesus D-Negative Antenatal Population: The Usefulness of Conventional Polymerase Chain Reaction in Resource-limited Settings.

Authors:  Otchere Addai-Mensah; Edward Y Afriyie; Samuel Asamoah Sakyi; Christian Obirikorang; Max Efui Annani-Akollor; Eddie-Williams Owiredu; Francis A Amponsah; Richard Vikpebah Duneeh; Evans Asamoah Adu
Journal:  Obstet Gynecol Int       Date:  2020-10-16

4.  Prenatal non-invasive foetal RHD genotyping: diagnostic accuracy of a test as a guide for appropriate administration of antenatal anti-D immunoprophylaxis.

Authors:  Silvia Manfroi; Chiara Calisesi; Pietro Fagiani; Annalisa Gabriele; Gianluca Lodi; Simonetta Nucci; Susanna Pelliconi; Laura Righini; Vanda Randi
Journal:  Blood Transfus       Date:  2018-04-09       Impact factor: 3.443

5.  Algorithm development and diagnostic accuracy testing for non-invasive foetal RHD genotyping: an Indian experience.

Authors:  Disha Parchure; Manisha Madkaikar; Swati Kulkarni
Journal:  Blood Transfus       Date:  2021-03-31       Impact factor: 5.752

6.  Non-invasive prenatal rhesus D genotyping using cell-free foetal DNA.

Authors:  Riyaz Ahmad Rather; Veena Dhawan; Subhas Chandra Saha
Journal:  Indian J Med Res       Date:  2019-07       Impact factor: 2.375

7.  Diagnostic performance of the noninvasive prenatal FetoGnost RhD assay for the prediction of the fetal RhD blood group status.

Authors:  Tobias J Legler; Sandra Lührig; Irina Korschineck; Dieter Schwartz
Journal:  Arch Gynecol Obstet       Date:  2021-04-09       Impact factor: 2.344

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.